AIM ImmunoTech Inc. (AIM)
AIM ImmunoTech Inc.
2117 SW Highway 484
Ocala, FL 34473
United States
352 448 7797
https://aimimmuno.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 26
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Thomas K. Equels Esq., J.D., M.S. | Executive Vice Chairman, CEO & President | 953.19k | N/D | 1953 |
| Mr. Robert Dickey IV, M.B.A. | Chief Financial Officer | 64.48k | N/D | 1956 |
| Mr. Peter W. Rodino III, Esq., J.D. | COO, Executive Director of Governmental Relations, General Counsel & Secretary | 484.94k | N/D | 1951 |
| Ann Marie E. Coverly | Director of Administration & Human Resources and Deputy Investor Relations Coordinator | N/D | N/D | N/D |
| Dr. Carol A. Smith | Chief Manufacturing Officer & Deputy Chief Scientific Officer | 170.77k | N/D | 1951 |
| Dr. Christopher McAleer Ph.D. | Scientific Officer | N/D | N/D | N/D |
| Dr. Ralph Christopher Cavalli Ph.D. | Vice President of QC & Manufacturing | 234.79k | N/D | 1958 |
Descripción
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Gestión corporativa
La calificación ISS Governance QuickScore de AIM ImmunoTech Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
